Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab, Lenalidomide, and Tafasitamab in R/R DLBCL
NCT07030699Phase 2Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2025
- Primary completion
- Mar 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Memorial Sloan Kettering Cancer Center. Planned start Aug 2025; status: withdrawn.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07030699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07030699.